BioCentury
ARTICLE | Company News

Sumitomo Dainippon to bolster pipeline via deal for women's health, urology, rare disease vants for $3B

September 6, 2019 11:12 PM UTC

Sumitomo Dainippon will pay $3 billion to acquire Roivant's stakes’ in five of its “vants” encompassing women's health, urology and rare diseases, propping up its pipeline as it anticipates losing U.S. market exclusivity on antipsychotic Latuda lurasidone and discontinues pancreatic cancer candidate napabucasin.

Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) is paying Roivant Sciences GmbH (Basel, Switzerland) about half of the Japanese company’s market cap of $6.7 billion to assume Roivant's ownership in Myovant Sciences GmbH (NYSE:MYOV), Urovant Sciences Ltd. (NASDAQ:UROV), pediatric rare disease and respiratory rare disease subsidiaries Enzyvant Sciences GmbH and Altavant Sciences Inc., and an undisclosed vant. ...